Lifeboat Foundation

New tools are steadily bridging this gap. And ongoing development of one particular technique, cryo-electron tomography, or cryo-ET, has the potential to deepen how researchers study and understand how cells function in health and disease.

As the former editor-in-chief of Science magazine and as a researcher who has studied hard-to-visualize large protein structures for decades, I have witnessed astounding progress in the development of tools that can determine biological structures in detail. Just as it becomes easier to understand how complicated systems work when you know what they look like, understanding how biological structures fit together in a cell is key to understanding how organisms function.

New study claims an increase in mice median remaining lifespan of 109% via Gene Therapy Mediated Partial Reprogramming.

My full supplement stack: https://drstanfield.com/my-supplements/
Supplements I source from Amazon: http://amzn.to/3o2ULOV

Continue reading “Epigenetic Reprogramming Extends Remaining Lifespan” »

Ralph Lydic, professor in the UT Department of Psychology, and Dmitry Bolmatov, a research assistant professor in the UT Department of Physics and Astronomy, are part of a UT/ORNL research team studying how bio-inspired materials might inform the design of next-generation computers. Their results, published recently in the Proceedings of the National Academy of Sciences, could have big implications for both edge computing and human health.

Scientists at ORNL and UT discovered an artificial cell membrane is capable of long-term potentiation, or LTP, a hallmark of biological learning and memory. This is the first evidence that a cell membrane alone—without proteins or other biomolecules embedded within it—is capable of LTP that persists for many hours. It is also the first identified nanoscale structure in which memory can be encoded.

“When facilities were shut down as a result of COVID, this led us to pivot away from our usual membrane research,” said John Katsaras, a biophysicist in ORNL’s Neutron Sciences Directorate specializing in neutron scattering and the study of biological membranes at ORNL. “Together with postdoc Haden Scott, we decided to revisit a system previously studied by Pat Collier and co-workers, this time with an entirely different electrical stimulation protocol that we termed ‘training.’”.

A variety of healthy eating patterns are linked to reduced risk of premature death, according to a new study led by Harvard T.H. Chan School of Public Health researchers. They found that participants who scored high on adherence to at least one of four healthy eating patterns were less likely to die during the study period from any cause and less likely to die from cardiovascular disease, cancer, or respiratory disease, compared with people with lower scores. The findings are consistent with the current Dietary Guidelines for America, which recommend multiple healthy eating patterns.

“The Dietary Guidelines for Americans are intended to provide science-based dietary advice that promotes good health and reduces major chronic diseases. Thus, it is critical to examine the associations between DGAs-recommended dietary patterns and long-term health outcomes, especially mortality,” said corresponding author Frank Hu, Fredrick J. Stare Professor of Nutrition and Epidemiology and chair of the Department of Nutrition.

The study will be published online January 9, 2023, in JAMA Internal Medicine.

Pioneering Hematopoietic Stem Cell Transplants (HSCT) For Autoimmune Disorders — Dr. Richard K. Burt

Dr. Richard K. Burt MD (https://astemcelljourney.com/about/drrichardburt/) is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University where he served as Chief of Immunotherapy and Autoimmune Diseases, and CEO of Genani Biotechnology.

Continue reading “Dr. Richard Burt MD — Pioneering Hematopoietic Stem Cell Transplants (HSCT) For Autoimmune Disorders” »

Newspaper headlines from the U.S. to the U.K. and most places in between highlight the surge in sick patients suffering from respiratory viruses. The so-called “tripledemic” of lung infections including respiratory synclinal virus (RSV), influenza (flu) and COVID-19 (coronavirus) is likely to last throughout the winter season. This explosion of infections requires more treatment options to support overloaded hospitals and overworked medics as they restore people’s health.

It has been known for a long time that intubation of an infant with any lung condition, or even an adult with severe COVID-19 using either ventilation or extra-corporeal membrane oxygenation (ECMO), comes with risks and side effects that could cause permanent damage not limited to the lungs. However, hypoxia, which means oxygen deficiency, is a medical emergency that is a common complication of severe lung infections. If not treated, it can lead to severe disability and even death.

UNIGE researchers have discovered that a medication commonly used to treat herpes can combat an antibiotic-resistant bacterium by disrupting its defense mechanisms.

Antibiotic resistance, or the ability of bacteria to develop resistance to treatment with antibiotics, has become a major concern for global health. The World Health Organization (WHO) considers it one of the greatest threats to health. The overuse of antibiotics has contributed to the emergence of antibiotic-resistant bacteria, which can cause serious illness and death. One example of an antibiotic-resistant pathogen is Klebsiella pneumoniae, a bacterium commonly found in hospitals and known for its virulence. Without effective treatment options, we could see a resurgence of diseases such as pneumonia and salmonella, which were once easily treated with antibiotics.

Researchers at the University of Geneva (UNIGE) have found that edoxudine, an anti-herpes molecule developed in the 1960s, can disrupt the protective surface of Klebsiella bacteria and make them more vulnerable to being eliminated by immune cells. The researchers’ findings were recently published in the journal PLOS ONE.

January is National Glaucoma Awareness Month, which makes this a good time to learn more about treating this group of eye conditions.

About 3 million people in the U.S. have glaucoma, and it’s the second-leading cause of blindness worldwide, according to the Centers for Disease Control and Prevention.

Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high pressure in your eye. Elevated eye pressure is due to a buildup of the fluid that flows throughout the inside of your eye. When this fluid is overproduced or the drainage system doesn’t work properly, the fluid can’t flow out at its normal rate and eye pressure increases.

U.S. health regulators gave early approval to a new Alzheimer’s drug from Eisai Co. and Biogen Inc., the most promising to date in a new class of medicines that may help slow cognitive decline caused by the disease.

The Food and Drug Administration granted conditional approval to the drug, called lecanemab, based on an early study finding it reduced levels of a sticky protein called amyloid from the brains of people with early-stage Alzheimer’s. The companies will sell it under the brand name Leqembi.